Literature DB >> 30560339

Management of Non-tumoral Portal Vein Thrombosis in Patients with Cirrhosis.

Jonathan G Stine1,2, Patrick G Northup3.   

Abstract

Non-tumoral portal vein thrombosis (PVT) remains a highly relevant topic in the field of hepatology and liver transplantation with much surrounding controversy. Although multiple studies have shown that PVT is associated with adverse outcomes with increased morbidity and mortality rates, others have not reported the same clinical impact of PVT, arguing rather that incident PVT reflects worsening portal hypertension and the natural history of the disease. Despite this uncertainly, PVT is a dilemma facing the clinician on a daily basis often requiring a multidisciplinary team-based approach between hepatologists, transplant surgeons, interventional radiologists and hematologists. In this review, the authors provide a summary of the evidence supporting best clinical practices in the management of non-tumoral PVT in patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30560339     DOI: 10.1007/s10620-018-5427-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  49 in total

1.  Pretransplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein Thrombosis.

Authors:  Riad Salem; Michael Vouche; Talia Baker; Jose Ignacio Herrero; Juan Carlos Caicedo; Jonathan Fryer; Ryan Hickey; Ali Habib; Michael Abecassis; Felicitas Koller; Robert Vogelzang; Kush Desai; Bartley Thornburg; Elias Hohlastos; Scott Resnick; Robert J Lewandowski; Kent Sato; Robert K Ryu; Daniel Ganger; Laura Kulik
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

2.  Portal vein thrombosis and survival in patients with cirrhosis.

Authors:  Michael J Englesbe; James Kubus; Wajee Muhammad; Christopher J Sonnenday; Theodore Welling; Jeffrey D Punch; Raymond J Lynch; Jorge A Marrero; Shawn J Pelletier
Journal:  Liver Transpl       Date:  2010-01       Impact factor: 5.799

3.  Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis.

Authors:  Jonathan G Stine; Neeral L Shah; Curtis K Argo; Shawn J Pelletier; Stephen H Caldwell; Patrick G Northup
Journal:  Liver Transpl       Date:  2015-07-01       Impact factor: 5.799

4.  Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis.

Authors:  Kristin Berry; Justin Taylor; Iris W Liou; George N Ioannou
Journal:  Clin Gastroenterol Hepatol       Date:  2014-10-18       Impact factor: 11.382

5.  Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.

Authors:  Erica Villa; Calogero Cammà; Marco Marietta; Monica Luongo; Rosina Critelli; Stefano Colopi; Cristina Tata; Ramona Zecchini; Stefano Gitto; Salvatore Petta; Barbara Lei; Veronica Bernabucci; Ranka Vukotic; Nicola De Maria; Filippo Schepis; Aimilia Karampatou; Cristian Caporali; Luisa Simoni; Mariagrazia Del Buono; Beatrice Zambotto; Elena Turola; Giovanni Fornaciari; Susanna Schianchi; Anna Ferrari; Dominique Valla
Journal:  Gastroenterology       Date:  2012-07-20       Impact factor: 22.682

6.  Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation.

Authors:  C Francoz; J Belghiti; V Vilgrain; D Sommacale; V Paradis; B Condat; M H Denninger; A Sauvanet; D Valla; F Durand
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

7.  Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis.

Authors:  M Senzolo; K I Rodriguez-Castro; V Rossetto; C Radu; S Gavasso; P Carraro; P Zerbinati; M T Sartori; P Simioni
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

8.  Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis.

Authors:  Noriaki Naeshiro; Hiroshi Aikata; Hideyuki Hyogo; Hiromi Kan; Hatsue Fujino; Tomoki Kobayashi; Takayuki Fukuhara; Yohji Honda; Takashi Nakahara; Atsushi Ohno; Daisuke Miyaki; Eisuke Murakami; Tomokazu Kawaoka; Masataka Tsuge; Nobuhiko Hiraga; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hidenori Ochi; Kazuaki Chayama
Journal:  Hepatol Res       Date:  2014-09-02       Impact factor: 4.288

9.  Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation.

Authors:  M Senzolo; J Tibbals; E Cholongitas; C K Triantos; A K Burroughs; D Patch
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

Review 10.  Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab.

Authors:  Tiffany Y Hu; Vaibhav R Vaidya; Samuel J Asirvatham
Journal:  Vasc Health Risk Manag       Date:  2016-02-17
View more
  5 in total

1.  The clinical value of color Doppler ultrasonography in measuring the hemodynamics of liver cirrhosis patients' portal and splenic veins.

Authors:  Ran Hui; Zhe Li; Zongjie Liu; Xiuping Liu; Heping Deng
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Splanchnic Vein Thrombosis in Liver Cirrhosis After Splenectomy or Splenic Artery Embolization: A Systematic Review and Meta-Analysis.

Authors:  Yanyan Wu; Hongyu Li; Tiansong Zhang; Zhaohui Bai; Xiangbo Xu; Giovanni Battista Levi Sandri; Le Wang; Xingshun Qi
Journal:  Adv Ther       Date:  2021-03-09       Impact factor: 3.845

3.  Effect of transjugular intrahepatic portosystemic shunt combined with 125I particle implantation on portal vein tumor thrombus in hepatocellular carcinoma.

Authors:  Hongbo Han; Yanli Meng; Jitian Wang
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

4.  Transjugular intrahepatic portosystemic shunt assisted with trans-splenic access.

Authors:  Zhang Cheng; Feng Wang; Jianfei Liu
Journal:  Clin Mol Hepatol       Date:  2019-06-19

5.  Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial.

Authors:  Ting Zhou; Xin Sun; Tao Zhou; Yueyue Li; Xiaoning Chen; Baoquan Cheng; Yanjing Gao
Journal:  Clin Transl Gastroenterol       Date:  2020-09       Impact factor: 4.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.